Traders Purchase High Volume of ClearPoint Neuro Call Options (NASDAQ:CLPT)

Key Points

• ClearPoint Neuro experienced a significant jump in options trading, with 5,503 call options purchased, marking a **2,033% increase** from its typical daily volume of 258.
• Institutional investors have heavily invested in ClearPoint Neuro, with **Allworth Financial** increasing its stake by **3,076.9%** and other firms also acquiring substantial new positions.
• The stock's **price surged to $18.42** on Wednesday, with a trading volume of over **6 million shares**, indicating heightened investor interest following its earnings report, which showed a slight revenue beat despite a negative EPS.

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) saw some unusual options trading on Wednesday. Traders purchased 5,503 call options on the stock. This represents an increase of approximately 2,033% compared to the typical daily volume of 258 call options.

Institutional Trading of ClearPoint Neuro

Institutional investors have recently made changes to their positions in the company. Allworth Financial LP boosted its stake in shares of ClearPoint Neuro by 3,076.9% in the second quarter. Allworth Financial LP now owns 2,065 shares of the company's stock worth $25,000 after acquiring an additional 2,000 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in ClearPoint Neuro by 2,435.2% during the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company's stock worth $27,000 after buying an additional 2,143 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in ClearPoint Neuro during the second quarter worth $32,000. Legal & General Group Plc acquired a new position in ClearPoint Neuro during the second quarter worth $35,000. Finally, PNC Financial Services Group Inc. acquired a new position in ClearPoint Neuro during the second quarter worth $48,000. 30.08% of the stock is owned by institutional investors and hedge funds.

ClearPoint Neuro Price Performance

Shares of ClearPoint Neuro stock traded up $6.26 on Wednesday, reaching $18.42. The company's stock had a trading volume of 6,255,799 shares, compared to its average volume of 341,838. The company has a market capitalization of $523.65 million, a P/E ratio of -23.01 and a beta of 0.89. ClearPoint Neuro has a 52-week low of $9.76 and a 52-week high of $19.22. The stock has a 50-day moving average price of $10.88 and a 200-day moving average price of $11.93. The company has a quick ratio of 6.45, a current ratio of 7.30 and a debt-to-equity ratio of 1.46.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The firm had revenue of $9.22 million during the quarter, compared to analyst estimates of $9.20 million. ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Analysts expect that ClearPoint Neuro will post -0.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CLPT. Wall Street Zen raised ClearPoint Neuro from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Stifel Nicolaus raised their price target on ClearPoint Neuro from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $19.67.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.